Swansea University – Confidence in Concept 2019
Lead Research Organisation:
Swansea University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
People |
ORCID iD |
Publications
Bilbao-Asensio M
(2022)
Redox-Triggered Nanomedicine via Lymphatic Delivery: Inhibition of Melanoma Growth by Ferroptosis Enhancement and a Pt(IV)-Prodrug Chemoimmunotherapy Approach
in Advanced Therapeutics
Francis LW
(2021)
Highly glycosylated MUC1 mediates high affinity L-selectin binding at the human endometrial surface.
in Journal of nanobiotechnology
Howard D
(2022)
Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.
in Frontiers in oncology
Khan Z
(2021)
Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study.
in Frontiers in cellular and infection microbiology
Paradiso F
(2022)
Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer.
in Cells
Toubhans B
(2020)
Selenium nanoparticles trigger alterations in ovarian cancer cell biomechanics.
in Nanomedicine : nanotechnology, biology, and medicine
Toubhans B
(2023)
Selenium nanoparticles modulate histone methylation via lysine methyltransferase activity and S-adenosylhomocysteine depletion.
in Redox biology
| Description | AgorIP market review and IP protection |
| Amount | £35,000 (GBP) |
| Organisation | AgorIP |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2021 |
| End | 12/2022 |
| Description | EPSRC DTP |
| Amount | £95,000 (GBP) |
| Organisation | Houston Methodist Research Institute |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 10/2022 |
| End | 05/2026 |
| Title | Red Blood Cell Rheology |
| Description | Novel technique for characterising Rheology of red blood cells. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2022 |
| Provided To Others? | No |
| Impact | It is being used by Clinical Colleagues in an NHS setting. |
| Description | Induction of anti-tumour immunity and ferroptotic cell-death in the tumour microenvironment (TME) using engineered lipid coated iron oxide nanovaccines (IONVs) |
| Organisation | King's College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provided nanoparticles |
| Collaborator Contribution | In collaboration looking at macrophage phenotype in response to nanoparticles |
| Impact | TBD |
| Start Year | 2020 |
| Description | Loreal for SMART polymer nano-vectors for ovarian cancer |
| Organisation | L'Oreal (Paris) |
| Country | France |
| Sector | Private |
| PI Contribution | Initial discussion and data sharing |
| Collaborator Contribution | Initial discussion and data sharing |
| Impact | TBD |
| Start Year | 2022 |
| Description | Midatech Pharma (Cardiff) for SMART polymer nano-vectors for ovarian cancer |
| Organisation | Midatech Pharma PLC |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Discussion, data sharing and scoping of future relationship |
| Collaborator Contribution | Discussion, data sharing and scoping of future relationship |
| Impact | Multi-disciplinary partnership - outputs are a collaborative agreement to explore collaboration and future research, if and when appropriate |
| Start Year | 2021 |
| Description | SMART polymer nano-vectors for ovarian cancer |
| Organisation | University of Liverpool |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Initial discussion and data sharing |
| Collaborator Contribution | Initial discussion and data sharing |
| Impact | TBD |
| Start Year | 2022 |
| Description | Accepted abstract for The 7th ed. of Nanotech France 2022 Int. Conference and Exhibition |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | People attending conference will view abstract and have discussions relating to cutting edge content. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://setcor.org/conferences/nanotech-france-2022 |
| Description | Presentation to Clinical Colleagues |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dissemination of a new biomarker of red blood cells to Clinical Colleagues at Morriston Hospital. Talk was attended by 10 NHS Consultants, Junior Doctors, and Research Nurses. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Speaker at Annual BSNM conference, Swansea August 2022. 'Flexible Polymer drug delivery for HGSOC'. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Speaker at Annual BSNM conference, Swansea August 2022. 'Flexible Polymer drug delivery for HGSOC'. 300 people attended. Questions and discussions sparked and new contacts made. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.britishsocietynanomedicine.org/ |
| Description | Speaker at 6th Annual Formulation and Drug Delivery Congress, London, May 2022. 'Precision Medicine Technologies for Advanced Therapeutics; targeting the Ovarian Cancer Tumour Microenvironment.' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Speaker at 6th Annual Formulation and Drug Delivery Congress, London, May 2022. 'Precision Medicine Technologies for Advanced Therapeutics; targeting the Ovarian Cancer Tumour Microenvironment.' Also Session Chair and Academic expert in Industrial taskforce discussion group for BSNM. Reached 300 people. Discussion sparked and awareness generated. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.oxfordglobal.co.uk/formulation-delivery-series-uk/?utm_source=EventListing&%3Butm_med... |